Teva Inks $40.5B Deal For Allergan Generics Unit
Teva Pharmaceutical Industries Ltd., guided by Sullivan & Cromwell LLP, has inked a deal to pay $40.5 billion in cash and stock for the generic-drug business of Allergan plc instead of...To view the full article, register now.
Already a subscriber? Click here to view full article